Clinical trial
Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma
NCT02965157 is registered in ClinicalTrials.gov with Beijing Biohealthcare Biotechnology Co.,Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma
- Lead sponsor
- Beijing Biohealthcare Biotechnology Co.,Ltd
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- August 31, 2016
- Completion date
- Not reported
- Enrollment
- 15 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.